Trial Profile
Reduced-Intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2014
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Ciclosporin (Primary) ; Fludarabine (Primary) ; Melphalan (Primary) ; Methylprednisolone (Primary)
- Indications Chronic granulomatous disease; Haemophagocytic lymphohistiocytosis; Leucocyte disorders
- Focus Therapeutic Use
- Acronyms RICHI
- 28 Nov 2014 New trial record